Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Corporate Update (Sep 16, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed September 16, 2026
Period End
September 16, 2026
Security
HALO
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed September 16, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced on September 16, 2026 that it intends to offer, subject to market conditions and other factors, $1.05 billiona aggregate principal amount of convertible senior notes due 2033.

The company also expects to grant the initial purchasers a 13-day option to buy up to an additional $150 millionb of the notes. The notes are being offered only to qualified institutional buyers under Rule 144A, and the filing states they will be senior, unsecured obligations that accrue interest payable semi-annually and mature on October 1, 2033. Conversions will be settled in cash and, if applicable, shares of common stock, at the company's election.

The initial conversion rate, interest rate and other terms will be set at pricing. Halozyme states it expects to use a portion of the net proceeds to fund the cost of capped call transactions and to repurchase portions of its outstanding 0.25%c convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayment of the notes at maturity or upon early optional redemption.

The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the notes, and the capped calls are generally expected to reduce potential dilution from conversions. The filing is a notice of a proposed offering and does not state final pricing, size of the option exercise or closing results. The accompanying press release also describes the company's ENHANZE drug delivery technology, Hypercon and Surf Bio hyperconcentration technologies, and its Hylenex and XYOSTED commercial products.

Key Highlights

  1. Proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033, subject to market conditions
  2. Initial purchasers expected to receive a 13-day option to buy up to an additional $150 million of notes
  3. Notes to be senior, unsecured obligations with semi-annual interest and maturity on October 1, 2033
  4. Conversions to be settled in cash and, if applicable, shares of common stock, at the company's election
  5. Proceeds to partly fund capped call transactions and privately negotiated repurchases of 2027 and 2028 convertible notes
  6. Remaining net proceeds for general corporate purposes, including potential acquisitions and strategic transactions
  7. Offering is limited to qualified institutional buyers under Rule 144A; initial conversion rate, interest rate and other terms to be set at pricing

Frequently Asked Questions

  1. How much is Halozyme proposing to raise in this offering?

    Halozyme proposes to offer $1.05 billion aggregate principal amount of convertible senior notes due 2033, plus a 13-day option for initial purchasers to buy up to an additional $150 million of the notes.

  2. When do the new convertible notes mature?

    The notes are scheduled to mature on October 1, 2033, unless earlier redeemed, repurchased or converted under their terms.

  3. How will Halozyme use the proceeds?

    A portion will fund the cost of capped call transactions and privately negotiated repurchases of its 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028. The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayments.

  4. How could the capped call transactions affect shareholders?

    The company states that the capped calls are generally expected to reduce potential dilution to its common stock upon conversion and/or offset certain cash payments above the principal amount, up to the cap price. Above the cap price, dilution and payment obligations would not be offset to the extent the market price exceeds that level.

  5. Who can buy the notes and what terms are still undecided?

    The notes are offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A. The initial conversion rate, interest rate and other terms will be determined at pricing in negotiations with the initial purchasers.